A San Francisco, California-based medical device startup, Zenflow, has announced a $31.4 million Series A financing round to further its minimally-invasive approach to treating benign prostatic hyperplasia (BPH) or enlarged prostate.
New research suggests that men with abnormally low levels of testosterone are less likely to develop prostate cancer in their lifetime. The new study was carried out by scientists at the University of Oxford in the United Kingdom, and the findings were presented at the National Cancer Research Institute (NCRI) Cancer Conference, held in Liverpool, U.K.
Androgen-deprivation therapy, which is a common treatment for prostate cancer, has been tentatively linked with an increased risk of cardiovascular disease. A new study solidifies these concerns.
Scientists from the Cancer Biomarkers laboratory team of the Institute of Cancer Research in the UK have carried out research to demonstrate the use of a quick genetic test for the targeted treatment of prostate cancer.
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.